Literature DB >> 17293026

Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection.

Alberto Briganti1, Pierre I Karakiewicz, Felix K-H Chun, Andrea Gallina, Andrea Salonia, Giuseppe Zanni, Luc Valiquette, Markus Graefen, Hartwig Huland, Patrizio Rigatti, Francesco Montorsi.   

Abstract

OBJECTIVE: We hypothesized that the information stemming from biopsy cores can enhance the ability to predict the rate of lymph node invasion (LNI) at radical retropubic prostatectomy (RRP) in men subjected to extended pelvic lymphadenectomy (ePLND).
MATERIALS AND METHODS: A cohort of 278 consecutive patients (mean age: 66.2 yr) underwent a RRP and an ePLND, in which 10 or more nodes were removed and examined. The median PSA was 7.5 ng/ml. Clinical stage was mostly T1c (59.4%) and T2 (37.8%). Biopsy Gleason sum was 2-5 in 26.6%, 6 in 39.2%, 7 in 27%, and 8-10 in 7.2%. The number of positive cores was 1-19 (median: 4), whilst percentage of positive cores was 7.1-100% (median: 37.5%). Logistic regression models tested the association between the above predictors and LNI. Testing of PSA was coded as either a continuous variable (CV) or a cubic spline (CS). Individual variables and combined accuracy were tested in regression-based nomograms, which were subjected to 10,000 bootstrap resamples to reduce overfit bias.
RESULTS: Mean number of lymph nodes examined was 17.5 (range: 10-38); 29 patients (10.4%) had LNI. Percentage of positive cores (78.5%) and biopsy Gleason sum (78.4%) were the most informative predictors of LNI. A nomogram based on clinical stage, PSA (CV), and biopsy Gleason sum was 79.7% accurate versus 83% (3.3% gain, p<0.001) when percentage of positive cores was added. A 2.7% gain (83.7% vs. 81%; p<0.001) was recorded after the addition of the percentage of positive cores when PSA was coded as a CS.
CONCLUSIONS: Percentage of positive biopsy cores should be considered in prediction of LNI at ePLND, because it significantly improves the combined accuracy of established clinical predictors such as PSA, clinical stage, and biopsy Gleason sum.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293026     DOI: 10.1016/j.eururo.2007.01.108

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  21 in total

1.  Should all men having a radical prostatectomy have a pelvic lymph node dissection? No.

Authors:  Firas Abdollah; Maxine Sun; Rodolphe Thuret; Pierre I Karakiewicz
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

2.  Sentinel lymph node dissection combined with meticulous histology increases the detection rate of nodal metastases in prostate cancer.

Authors:  Michal Staník; Ivo Čapák; Daniel Macík; Jiří Vašina; Eva Lžičařová; Jiří Jarkovský; Martin Šustr; David Miklánek; Jan Doležel
Journal:  Int Urol Nephrol       Date:  2014-03-29       Impact factor: 2.370

3.  Current status of pelvic lymph node dissection in prostate cancer.

Authors:  Ilija Aleksic; Tyler Luthringer; Vladimir Mouraviev; David M Albala
Journal:  J Robot Surg       Date:  2013-12-11

Review 4.  Prostate cancer nomograms: a review of their use in cancer detection and treatment.

Authors:  R J Caras; Joseph R Sterbis
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

5.  Validation and head-to-head comparison of three nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended and/or sentinel lymph node dissection.

Authors:  Nikolaos Grivas; Esther Wit; Corinne Tillier; Erik van Muilekom; Floris Pos; Alexander Winter; Henk van der Poel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-05       Impact factor: 9.236

6.  Mapping of lymphatic drainage from the prostate using filtered 99mTc-sulfur nanocolloid and SPECT/CT.

Authors:  Youngho Seo; Carina Mari Aparici; Chien Peter Chen; Charles Hsu; Norbert Kased; Carole Schreck; Nick Costouros; Randall Hawkins; Katsuto Shinohara; Mack Roach Iii
Journal:  J Nucl Med       Date:  2011-06-16       Impact factor: 10.057

7.  Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

Authors:  Jarrod B Adkison; Derek R McHaffie; Søren M Bentzen; Rakesh R Patel; Deepak Khuntia; Daniel G Petereit; Theodore S Hong; Wolfgang Tomé; Mark A Ritter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-14       Impact factor: 7.038

Review 8.  The role of lymph node dissection in the management of prostate cancer.

Authors:  Jun Miki; Shin Egawa
Journal:  Int J Clin Oncol       Date:  2011-05-10       Impact factor: 3.402

Review 9.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 10.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.